Y-mAbs(YMAB) ZACKS·2025-02-03 15:35Core Viewpoint - Y-mAbs Therapeutics, Inc. (YMAB) is experiencing significant selling pressure, with a 26.9% decline over the past four weeks, but is now positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - YMAB's current RSI reading is 20.9, suggesting that the heavy selling may be exhausting, indicating a possible bounce back towards equilibrium [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for YMAB will improve, with a 2.6% increase in the consensus EPS estimate over the last 30 days [6]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6]. Group 3: Analyst Ratings - YMAB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7].